替吉奥在晚期胃癌患者维持治疗的临床研究

目的：观察替吉奥在晚期胃癌患者维持治疗的疗效、临床受益率和不良反应。方法：42例初诊为晚期胃癌的患者，经过氟尿嘧啶类组成的联合化疗方案化疗4-6周期，化疗后部分缓解（PR）或稳定（SD）的患者，被随机分为替吉奥维持组和观察组。替吉奥维持组采用替吉奥单药口服，连用4周，停药2周，6周为一个周期。观察组不予任何治疗。治疗2个周期后评价疗效。结果：替吉奥维持组总有效率为42.9%，临床受益率为85.7%，中位疾病进展时间为4.5个月，中位总生存期为7.5个月；观察组总有效率为33.3%，临床受益率为80.9%，中位疾病进展时间为3.0个月，中位总生存期为6.5个月；两组近期疗效、中位疾病进展时间比较差异有统计学意义（P〈0.05），临床受益率、不良反应的发生率、总生存时间组间比较差异无统计学意义（P﹥0.05）。结论：替吉奥在晚期胃癌患者维持治疗疗效肯定、可取得较好的生存质量，毒副作用小。

Clinical Study of S-1 in the Maintenance Therapy of Patients with Advanced Gastric Cancer

Objective：To evaluate the clinical efficacy,the clinical benefit response and adverse reaction of S-1 in the ma-intenance therapy of patients with advanced gastric cancer. Methods：Forty-two patients with advanced gastric cancer un-derwent combined chemotherapy of fluorouracil in 4 - 6 cycles. The PR or SD patients were divided into S-1 group and observation group after chemotherapy. For the S-1 group,6 weeks constituted a cycle. Among the cycle,4 weeks for S-1 taking,2 weeks for withdrawl. In the observation group,no treatment was performed. Curative efficacy was assessed af-ter 2 cycles. Results：The total response rate of S-1 group was 42. 9% and 33. 3% of the observation group and the TTP were 4. 5 months and 3. 0 months respectively;there were significant difference between the two groups（P 〈 0. 05）. The clinical benefit response of S-1 group was 85. 7% and 80. 9% of the observation group and the MST were 7. 5 months and 6. 5 months respectively. There were no difference between the two groups（P ﹥ 0. 05）. Conclusions：The S-1 shows positive effect for patients with advanced gastric cancer in the maintenance therapy. It can achieve a better quality of life and small side effects for the patients.